Chronic Migraine Prophylaxis (≥15 Headache Days/Month)
Investigational adjunct for chronic migraine (≥15 days/month, ≥8 migrainous) refractory to two preventive classes; distinct from episodic migraine.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for chronic migraine prophylaxis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use here is investigational.
- What evidence exists?
- Tier C (investigational). There are no published controlled trials of leech therapy for chronic migraine prophylaxis. Evidence-based options include FDA-approved CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) with strong RCT support, FDA-approved onabotulinumtoxinA for chronic migraine (PREEMPT trials), topiramate, propranolol or other beta-blockers, amitriptyline, venlafaxine, and behavioral therapies (CBT, biofeedback). Acute therapy: triptans, gepants, ditans, NSAIDs. Avoidance of medication-overuse headache is critical.
- Main risks
- Bleeding from each bite site for 6 to 24 hours after detachment
- Bruising over the temporal or periorbital region for 5 to 10 days
- Local skin or, rarely, Aeromonas hydrophila infection
- Allergic reaction to leech saliva (uncommon)
- TRIGGER RISK: many migraine patients have specific triggers; placement may precipitate attacks
- Worsening of migraine for 1 to 3 days following sessions
- Delay of FDA-approved CGRP monoclonal antibodies, onabotulinumtoxinA, topiramate, propranolol
- Placebo response masking medication-overuse headache or secondary causes
- Who should not consider this
- Patients with red-flag headache features (sudden onset, neurological deficits, fever, immunosuppression, age over 50 new-onset)
- Patients with medication-overuse headache who need analgesic detoxification first
- Patients who have not tried CGRP monoclonal antibodies, onabotulinumtoxinA, topiramate, propranolol, or other RCT-supported preventives
- Patients with active dermatitis or broken skin at planned placement sites
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients (migraine prevention strategy is different in pregnancy)
- What to ask your clinician
- Have I tried CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) or gepants?
- Am I a candidate for onabotulinumtoxinA (Botox) using the PREEMPT protocol for chronic migraine?
- Have I tried topiramate, propranolol, amitriptyline, or other RCT-supported preventives at adequate doses?
- Am I using acute therapy more than 10 to 15 days per month (medication-overuse headache risk)?
- Have I tried CBT, biofeedback, lifestyle modification, sleep optimization, and trigger management?
- Why is leech therapy being considered given highly effective FDA-approved options for migraine?
- What is the practitioner's plan if I have a migraine attack during or after a session?
- When to seek urgent care
- Thunderclap (worst-of-life) headache (possible subarachnoid hemorrhage - 911)
- Headache with fever, stiff neck, photophobia, or altered mental status (possible meningitis)
- Headache with focal neurological deficit, persistent vision change, speech difficulty, or seizure
- Jaw claudication, scalp tenderness, or vision change in age over 50 (possible giant cell arteritis)
- Migraine with aura lasting more than 1 hour, or atypical aura
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or throat swelling, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for migraine prophylaxis.
- No controlled trials support efficacy; FDA-approved CGRP monoclonal antibodies and onabotulinumtoxinA have transformed chronic migraine treatment.
- It does not replace evidence-based prevention with the strongest RCT support.
- Medication-overuse headache must be addressed first if present.
- Migraine triggers vary by patient - placement may precipitate rather than prevent attacks.
Safety cross-references
Clinical Profile
- Category
- neurological
- ICD-10
- G43.701, G43.711, G43.719, G43.A0, G43.A1
- Safety tier
- low
Evidence Summary
Chronic migraine is defined per ICHD-3 as ≥15 headache days/month for ≥3 months with ≥8 migrainous features. Preventive options include topiramate, propranolol, candesartan, onabotulinumtoxinA, and CGRP-targeted therapies (erenumab, fremanezumab, galcanezumab). Medication-overuse headache must be ruled out and addressed first. No controlled clinical trial or published prophylaxis series of leech therapy for chronic migraine has been reported; any use is investigational and mechanistic only, with no comparator-controlled data to support it.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Bahramsoltani M et al. (2020), n=22
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Medication-overuse headache without prior taper
- Secondary headache from undiagnosed cause
- Current ergot or triptan overuse
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.